Sandra Misale

List of Publications by Year
in descending order

22 papers	4,438 citations	361413 20 h-index	677142 22 g-index
22 all docs	22 docs citations	22 times ranked	7606 citing authors

#	Article	IF	Citations
1	Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. Cancer Discovery, 2022, 12, 924-937.	9.4	110
2	Anatomic position determines oncogenic specificity in melanoma. Nature, 2022, 604, 354-361.	27.8	44
3	Resistance is futile with fourth-generation EGFR inhibitors. Nature Cancer, 2022, 3, 381-383.	13.2	6
4	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. Cancer Discovery, 2021, 11, 126-141.	9.4	34
5	KRAS G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma. Clinical Cancer Research, 2021, 27, 2604-2612.	7.0	20
6	EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. Cancer Discovery, 2020, 10, 1129-1139.	9.4	245
7	HER2-Mediated Internalization of Cytotoxic Agents inERBB2Amplified or Mutant Lung Cancers. Cancer Discovery, 2020, 10, 674-687.	9.4	149
8	Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature Medicine, 2019, 25, 1422-1427.	30.7	144
9	Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy. Nature, 2019, 570, 112-116.	27.8	147
10	KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition. Clinical Cancer Research, 2019, 25, 796-807.	7.0	175
11	Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. Oncogene, 2018, 37, 4599-4610.	5.9	30
12	MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Science Translational Medicine, 2016, 8, 324ra14.	12.4	81
13	Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. Cancer Discovery, 2016, 6, 36-44.	9.4	258
14	Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2016, 108, .	6.3	111
15	Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. Clinical Cancer Research, 2015, 21, 2157-2166.	7.0	227
16	Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nature Communications, 2015, 6, 8305.	12.8	97
17	Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer. Science Translational Medicine, 2014, 6, 224ra26.	12.4	228
18	Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution. Cancer Discovery, 2014, 4, 1269-1280.	9.4	415

#	Article	IF	Citations
19	TGFÎ± and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells. Clinical Cancer Research, 2014, 20, 6429-6438.	7.0	101
20	KRAS gene amplification in colorectal cancer and impact on response to EGFRâ€targeted therapy. International Journal of Cancer, 2013, 133, 1259-1265.	5.1	154
21	STAT3 can serve as a hit in the process of malignant transformation of primary cells. Cell Death and Differentiation, 2012, 19, 1390-1397.	11.2	57
22	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature, 2012, 486, 532-536.	27.8	1,605